1. Occupational Safety and Health Administration (OSHA). OSHA work-practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. Am J Hosp Pharm 1986;43:1193–204.Google Scholar
2. American Society of Hospital Pharmacists. Safe handling of cytotoxic drugs. Am J Hosp Pharm 1984;41:81–7.Google Scholar
3. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic drugs. Am J Hosp Pharm 1990;47:1033–49.Google Scholar
4. American Society of Health-System Pharmacists. ASHP Guidelines on handling hazardous drugs. [Internet]. 2006 [cited 2016, Aug 22th]. Available from: http://www.ashp.org/DocLibrary/BestPractices/PrepGdlHazDrugs.aspx.
5. Occupational Safety and Health Administration. Section VI: Chapter 2–controlling occupational exposure to hazardous drugs. [Internet]. 1986 [cited Aug 22th, 2016]. Available from: https://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html
6. Canadian Society of Hospital Pharmacists. Hazardous pharmaceuticals (including cytotoxic drugs): guidelines for handling and disposal. [Internet]. 1997 [cited 2016, Aug 22th]. Available from: http://www.cshp.ca/dms/dmsView/1_G_Hazardous_Pharmaceuticals_1997.pdf.
7. National Institute for Occupational Safety and Health Alert. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. [Internet]. 2004 [cited 2016, Aug 22th]. Available from: http://www.cdc.gov/niosh/docs/2004-165/pdfs/2004-165.pdf.
8. National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2014. Cincinnati (OH): Department of Health and Human Services (US), Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. [Internet]. 2015 [cited 2016, Aug 22th]. Available from: www.cdc.gov/niosh/docs/2014-138/pdfs/2014-138.pdf.
9. Association paritaire pour la santé et la sécurité du travail du secteur affaires sociales. Guide de prévention – Manipulation sécuritaire des médicaments dangereux (GP65). [Internet]. 2008 [cited 2016, Aug 22th]. Available from: http://www.asstsas.qc.ca/dossier-thematiques/medicaments-dangereux.
10. Ordre des pharmaciens du Québec. Norme 1995.01. Préparation de produits stériles en pharmacie. [Internet]. 1995 [cited 2016, Aug 22th]. Available from: www.opq.org/fr-CA/publications/normes-de-pratique-et-lignes-directrices.
11. Ordre des pharmaciens du Québec. Norme 2014.01: Préparation de produits stériles en pharmacie. [Internet]. 2014 [cited 2016, Aug 22th]. Available from: www.opq.org/fr-CA/publications/normes-de-pratique-et-lignes-directrices.
12. Ordre des pharmaciens du Québec. Norme 2014.02: Préparation de produits stériles dangereux en pharmacie. Montréal (QC): Ordre des pharmaciens du Québec. [Internet]. 2014 [cited 2016, Aug 22th]. Available from: www.opq.org/fr-CA/publications/normes-de-pratique-et-lignes-directrices.
13. Bussières JF, Théorêt Y, Prot-Labarthe S, Larocque D. Program to monitor surface contamination by methotrexate in a hematology-oncology satellite pharmacy. Am J Health Syst Pharm 2007;64(5):531–5.Google Scholar
14. Bussières JF, Tanguay C, Touzin K, Langlois E, Lefebvre M. Environmental contamination with hazardous drugs in Quebec hospitals. Can J Hosp Pharm 2012;65(6):428–35.Google Scholar
15. Merger D, Tanguay C, Langlois E, Lefebvre M, Bussières JF. Multicenter study of environmental contamination with antineoplastic drugs in 33 Canadian hospitals. Int Arch Occup Environ Health 2014 Apr;87(3):307–13.Google Scholar
16. Berruyer M, Tanguay C, Caron NJ, Lefebvre M, Bussières JF. Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: a 2013 follow-up study. J Occup Environ Hyg 2015;12(2):87–94.Google Scholar
17. Janes A, Tanguay C, Caron NJ, Bussières JF. Environmental Contamination with Cyclophosphamide, Ifosfamide, and Methotrexate: A Study of 51 Canadian Centres. Can J Hosp Pharm 2015 Jul-Aug;68(4):279–89.Google Scholar
18. Poupeau C, Tanguay C, Caron NJ, Bussières JF. Multicenter study of environmental contamination with antineoplastic drugs in 47 Canadian hospitals. Professionnal Practice Conference. Canadian Society of Hospital Pharmacists, 1–3 février 2016, Toronto, ON, CA.
19. Larson RR, Khazaeli MB, Dillon HK. Monitoring method for surface contamination caused by selected antineoplastic agents. Am J Health Syst Pharm 2002;59(3):270–7.Google Scholar
20. Sessink PJ, Trahan J, Coyne JW. Reduction in surface contamination with cyclophosphamide in 30 US hospital pharmacies following implementation of a closed-system drug transfer device. Hosp Pharm 2013;48(3):204–12.Google Scholar
21. Simon N, Vasseur M, Pinturaud M, Soichot M, Richeval C, Humbert L, et al. Effectiveness of a closed-system transfer device in reducing surface contamination in a new antineoplastic drug-compounding unit: a prospective, controlled, parallel study. PLoS One 2016;11(7):e0159052.Google Scholar
22. Hon CY, Teschke K, Chu W, Demers P, Venners S. Antineoplastic drug contamination of surfaces throughout the hospital medication system in Canadian hospitals. J Occup Environ Hyg 2013;10(7):374–83.Google Scholar
23. Connor TH, DeBord DG, Pretty JR, Oliver MS, Roth TS, Lees PS, et al. Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers. J Occup Environ Med 2010;52(10):1019–27.Google Scholar
24. Sugiura S, Nakanishi H, Asano M, Hashida T, Tanimura M, Hama T, et al. Multicenter study for environmental and biological monitoring of occupational exposure to cyclophosphamide in Japan. J Oncol Pharm Pract 2011;17(1):20–8.Google Scholar
25. Viegas S, Pádua M, Veiga AC, Carolino E, Gomes M. Antineoplastic drugs contamination of workplace surfaces in two Portuguese hospitals. Environ Monit Assess 2014;186(11):7807–18.Google Scholar
26. Poupeau C, Tanguay C, Plante C, Gagné S, Caron NJ, Bussières JF. Pilot study of biological monitoring of four antineoplastic drugs among Canadian healthcare workers. J Oncol Pharm Pract 2016 Apr 15.
About the article
Christel Roland is a Pharm.D candidate at Université de Lille. Currently, she is completing a residency at CHU Sainte-Justine and she is involved in environmental surveillance of hazardous drugs.
Johann-François Ouellette-Frève, pharmacist, obtained his Pharm.D in 2011 and his Master of Science in advanced pharmacotherapy in 2012. He is currently pharmacist at the oncology clinic, pharmacist in charge of the cellular therapy program and the coordinator of the hemato-oncology pharmacy team including the operation of the pharmacy satellite.
Caroline Plante, nurses, obtained her baccalaureate in 1997 and her certification of Canadian nurses association specializes in oncology in 2011. She is currently a nurse educator at CHU Sainte-Justine hospital in the hematology, oncology department for 5 years.
Jean-François Bussières, pharmacist, obtained his B.Pharm in 1988 and his Master of Science in 1992 from Université Laval and his Masters of Business Administration from McGill Université de Montreal, in1992. In 1996, he became Director of the Pharmacy Department of CHU Sainte-Justine. In addition, he combines the functions of Director of the Pharmacy Practice Research Unit, Full Clinical professor at the Faculty of Pharmacy, Université de Montréal and Guest speaker at the Faculty of pharmacy at Université Laval. He received numerous awards for excellence, including the Louis-Hébert Award in 2000 from the Ordre des pharmaciens du Québec, the Innovation Award in 2013 from the same authority, the National Excellence in Education in 2016 from the Association of Faculties of Pharmacy in Canada and the International Leadership Award in 2016 from the Canadian Pharmacists Association.
Published Online: 2016-10-20
Published in Print: 2016-12-01
Conflicts of interest statement: The authors state no conflict of interest. They have read the journal’s publication ethics and publication malpractice statement available at the journal’s website and hereby confirm that they comply with all its parts applicable to the present scientific work.